Organization (Industry)
Medela (Switzerland)
ClinicalTrials.gov lists Medela (Switzerland) as lead sponsor of 10 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Medela (Switzerland): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 2 |
| Diabetic Foot | 2 |
| Diabetic Neuropathies | 2 |
| Pressure Ulcer | 2 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 3 |
| 2014 | 1 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 4 of 4 hit target (n=4) | 2 of 4 on time (n=4) |
Journals published in (10)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery | 4 |
| The Annals of thoracic surgery | 4 |
| Thoracic surgery clinics | 2 |
| Acta obstetricia et gynecologica Scandinavica | 1 |
| Chest | 1 |
Showing 5 of 10 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 295 | 35 | 2025-12-30 |
FDA recalls (4)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Brand Name: Medela Product Name: ENFit ExSet Strl 60 2.0ml PV 1ct EN Model/Catalog Number: ENF060182LD / 101033086 Software Version: N/A Product Description: Enteral Extension Set, Length 60 Orange-Striped Minibore Tubing, (Approx. Priming Vol. 2.00 mL), ENFit¿ Component: N/A | Class II | 2026-06-05 |
| Invia Foam Dressing Kit with FitPad - X-Large (3 pcs) SKU # 0876224. The Invia Foam Dressing Kit with FitPad consists of a foam pad, a section interface (Invia FitPad) and Transparent Film (one or more pieces depending on the kit size). | Class II | 2019-12-02 |
| Breast Milk Transfer Lid for use with Oral Syringe Connectors Model: 90003S-100 | Class III | 2018-12-05 |
| Invia Motion Negative Pressure Wound Therapy System. Labeled as: a. Endure Negative Pressure Wound Therapy (Model 087.4010); b. 15 Days Negative Pressure Wound Therapy (Model 087.4012); c. 60 Days Negative Pressure Wound Therapy (Model 087.4014); d. Endure Negative Pressure Wound Therapy (Model 087.4020 ); e. 15 Days Negative Pressure Wound Therapy (Model 087.4022); f. 60 Days Negative Pressure Wound Therapy (Model 087.4024). Product Usage: The Invia Motion Negative Pressure Wound Therapy (NPWT) system is indicated for patients who would benefit from a suction device (NPWT) as it creates an environment that promotes wound healing by secondary or tertiary (delayed primary) intention by preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and perfusion, and by removing exudate and infectious material. | Class II | 2018-02-07 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2017-01-23 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| MEDELA AG | BAAR Zug, CH | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Co sponsors trial with | 1 |
Latest dated events (318)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-05 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-11-05 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-10-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 318 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ERAS | Trial collaborator | Named in trial inclusion criteria |
| ERAS | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.